logo
  

AstraZeneca Presents Exploratory Sub-analyses From HIMALAYA And TOPAZ-1 Trials

AstraZeneca (AZN.L, AZ) presented data for IMFINZI combinations from the HIMALAYA and TOPAZ-1 Phase III trials. The company said the HIMALAYA results showed a consistent survival benefit with the STRIDE regimen in patients with unresectable liver cancer regardless of baseline liver functional reserve. TOPAZ-1 data showed that IMFINZI plus chemotherapy improved outcomes for biliary tract cancer patients regardless of where their tumor was located or where they lived.

"These important subgroup analyses add to the body of evidence demonstrating the potential for IMFINZI combinations to meaningfully improve outcomes for these patients who are in need of effective and generally well tolerated treatments," said Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement retailer Lowe's Cos., Inc. reported Wednesday an increase in earnings per share for the second quarter that also topped analysts' estimates. However, quarterly sales edged down and missed expectations. The company also reaffirmed its guidance range for the full-year 2022. While reporting financial results for the second quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided financial outlook for the third and the fourth quarters as well as slashed its guidance for the full-year 2023. For the third quarter, the company projects earnings in a range... American Airlines announced an agreement to purchase up to 20 Overture supersonic jets, the world's fastest airliner, from transportation start-up Boom Supersonic, with an option for an additional 40. Overture, which is expected to carry passengers at twice the speed of the fastest commercial aircraft available at present, would provide an important new speed advantage to American's fleet.
Follow RTT